Posted by Michael Wonder on 07 Feb 2026
Kisqali receives positive draft recommendation from Canada's Drug Agency for all eligible early breast cancer patients at high risk of recurrence
6 February 2026 - The draft recommendation for Kisqali (ribociclib tablets) from Canada's Drug Agency (CDA-AMC) supports public reimbursement for hormone receptor positive, human epidermal growth factor receptor 2 negative stage II-III early breast cancer in patients at high risk of recurrence.
Novartis Canada applauds Canada's Drug Agency (CDA-AMC) for its positive draft recommendation to reimburse Kisqali (ribociclib tablets) for all eligible early breast cancer patients at high risk of recurrence.
